Wearing Off in Parkinson Disease: The Value of New Generation COMT Inhibition

Program Overview

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Clinical Case of 46-Year-Old Victor: Initial Presentation

Victor: Presenting Symptoms

Victor: On Examination

Clinical Case: Clinician Perspective on Diagnosis (I)

Clinical Case: Clinician Perspective on Diagnosis (II)

Early Non-Motor Signs of PD

Rationale for Medical Treatment of Victor

Current First-Line Treatments for PD: Benefits and Limitations

Clinician Treatment Recommendation for Victor

Case Continuation: Initial Treatment Approach

Case Continuation: Treatment Follow-up

Clinician Treatment Recommendation for Victor

Victor: Next Treatment Step

Victor: 3 Years Later

Characteristics and Mechanisms of Levodopa-Related Motor Fluctuations in PD

Early Morning Off Is Prevalent in all PD Stages: EUROPAR Study

EUROPAR Study: NMS during EMO

Approaches to Address Motor Fluctuations

Approaches to Address Motor Fluctuations: Add-on Treatments

Mechanism of COMT Inhibition

COMT Inhibitors: Entacapone, Tolcapone, and Opicapone

Entacapone and Tolcapone: Reduction in Off- Time

BIPARK I: Change in Absolute "Off" Time in Hours

Most Common AEs With Opicapone and Entacapone

One-Year Open-label Extension of BIPARK: Results for "Off" Time

BIPARK-I and -II: Tolerability

Retrospective Analysis of the Opicapone Treatment in a PD Clinic in Germany 

Retrospective Analysis of Opicapone Treatment in Germany: Tolerability

Practical Experience With Switching From Entacapone to Opicapone

Combined COMT Inhibition and Intrajejunal Levodopa Infusion: Single-Center Experience

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations (cont)